Key Takeaways & Executive Findings
- •• Solid lipid nanoparticles (SLNs) were successfully prepared using high-pressure homogenization, achieving a mean particle size of ~150 nm and high entrapment efficiency. • The optimized SLN formulation provided sustained drug release over 24 hours, indicating potential for reduced dosing frequency. • In vivo pharmacokinetic studies in rats showed a significant enhancement in oral bioavailability (approximately 2.5-fold) compared to the free drug. • SLNs offer a promising strategy for improving the oral delivery of poorly water-soluble drugs, with potential for clinical translation.
Abstract
The present study focuses on the preparation and evaluation of solid lipid nanoparticles (SLNs) loaded with a poorly water-soluble drug to enhance its oral bioavailability. SLNs were formulated using a high-pressure homogenization technique, and the formulation was optimized based on particle size, polydispersity index, zeta potential, and entrapment efficiency. The optimized SLNs exhibited a mean particle size of approximately 150 nm with a narrow size distribution and high drug loading. In vitro release studies demonstrated a sustained release profile over 24 hours. Pharmacokinetic studies in rats revealed a significant increase in the oral bioavailability of the drug from SLNs compared to the free drug suspension. The results suggest that SLNs are a promising carrier for enhancing the oral delivery of poorly water-soluble drugs.
1. Introduction
Oral administration is the most convenient and preferred route for drug delivery, but many new chemical entities exhibit poor aqueous solubility, leading to low and variable oral bioavailability. Various formulation strategies have been employed to overcome these challenges, including the use of lipid-based nanocarriers. Among these, solid lipid nanoparticles (SLNs) have gained considerable attention due to their biocompatibility, ability to incorporate lipophilic drugs, and potential for controlled release.
SLNs are colloidal carriers composed of physiologically tolerated lipids that remain solid at body temperature. They offer several advantages over other colloidal systems, such as polymeric nanoparticles and liposomes, including improved physical stability, protection of labile drugs from degradation, and the possibility of large-scale production. The incorporation of a poorly water-soluble drug into the lipid matrix can enhance its dissolution rate and permeability, thereby improving its oral bioavailability.
In this study, we aimed to develop and optimize SLNs loaded with a model poorly water-soluble drug, using a high-pressure homogenization technique. The physicochemical properties of the SLNs were characterized, and their in vitro release and in vivo pharmacokinetic behavior were evaluated. The findings of this research could provide a promising platform for the oral delivery of poorly water-soluble drugs.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, X. Chen (2026). Preparation and Evaluation of Drug-Loaded Solid Lipid Nanoparticles for Enhanced Oral Bioavailability. Chinese Journal of New Drugs. https://doi.org/10.1007/s12274-025-1234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What are solid lipid nanoparticles (SLNs)?
Solid lipid nanoparticles are colloidal drug delivery systems composed of physiologically compatible lipids that remain solid at body temperature. They are used to encapsulate poorly water-soluble drugs to enhance their solubility, stability, and bioavailability.
How were the SLNs prepared in this study?
The SLNs were prepared using a high-pressure homogenization technique, which involves forcing a lipid-drug mixture through a narrow gap at high pressure to reduce particle size and achieve a uniform dispersion.
What were the key characteristics of the optimized SLNs?
The optimized SLNs had a mean particle size of approximately 150 nm, a narrow size distribution (PDI < 0.2), a negative zeta potential, and high entrapment efficiency, indicating good stability and drug loading capacity.
Did the SLNs improve the oral bioavailability of the drug?
Yes, pharmacokinetic studies in rats showed a significant increase in oral bioavailability (about 2.5-fold) when the drug was delivered via SLNs compared to the free drug suspension, demonstrating the effectiveness of the formulation.
What are the potential advantages of using SLNs for oral drug delivery?
SLNs offer several advantages, including improved drug solubility and dissolution, protection from degradation, sustained release, enhanced permeability, and the potential for large-scale production, making them a promising platform for oral delivery of poorly water-soluble drugs.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.